

**Supplementary Table 2.** Proportions of prescription of antidiabetic medications in adults with diabetes mellitus from the Korean NHIS data, 2002–2018

Variable	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Total no.	967,046	1,186,000	1,341,796	1,589,387	1,766,632	1,916,923	2,064,729	2,225,526	2,329,323	2,503,965	2,643,903	2,779,560	2,937,155	3,073,395	3,289,900	3,500,672	3,726,248
Metformin	48.80	52.79	55.80	57.39	60.23	63.96	66.64	70.30	73.40	78.22	81.02	82.89	83.92	84.63	85.12	85.51	85.85
SGLT2i	0	0	0	0	0	0	0	0	0	0	0	0	0.59	2.40	4.68	6.87	8.09
GLP-1 RA	0	0	0	0	0	0	0	0	0.01	0.07	0.07	0.05	0.03	0.04	0.18	0.54	0.82
DPP-4i	0	0	0	0	0	0	0.31	7.64	11.88	18.56	27.97	37.34	44.39	52.11	57.87	60.53	61.98
TZD	7.05	8.95	10.02	10.51	11.17	10.44	11.15	12.73	11.10	8.12	6.57	6.43	8.56	10.02	10.73	10.95	11.33
AGI	23.68	24.09	22.78	22.18	24.20	24.69	24.76	22.89	21.03	18.18	13.14	9.26	6.92	5.03	3.61	2.69	2.05
SU/GLN	84.34	85.18	85.47	85.71	85.47	85.39	83.98	79.29	73.83	68.02	63.06	59.10	55.14	51.27	47.73	45.22	43.16
Insulin	21.18	22.13	22.27	21.74	22.79	22.81	23.12	22.63	22.37	21.62	21.17	20.22	19.53	18.97	18.62	18.16	17.83

Values are presented as numbers or percentages.

NHIS, National Health Insurance Service; SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; AGI,  $\alpha$ -glucosidase inhibitor; SU, sulfonylurea; GLN, glinide.